On the other hand, NK cells can directly affect the life of autoreactive T cells or APCs; in MS patients treated with IFNβ (194) or with the anti-CD25 antibody daclizumab, there is a selective expansion and activation of CD56bright NK cells and this correlates with a down-regulation of T cells activation and inhibition of inflammation (195, 196), suggesting that CD56bright NK cells are relevant in the control of MS lesions. The gene discussed is IFNB1; the disease is myeloid sarcoma.